Please assess the completion status of the following clinical trial:

Trial Title: TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least a 6 month history of probably migraine (6 migraine attacks per month)~* Males and women of childbearing potential on a adequate contraception.~Exclusion Criteria:~* Physician diagnosis of migraine; history of triptan or ergot use; history of headache prophylaxis use~* Pregnant and/or nursing mother~* History of cardiovascular disease.~* Uncontrolled hypertension.~* Basilar or Hemiplegic migraine~* History of stroke or transient ischemic attacks (TIA).~* History of epilepsy or treated with anti-epileptics within the past 5 years.~* Impaired hepatic or renal function.~* History of gastrointestinal bleeding or ulceration.~* Allergy or hypersensitivity to Aspirin or any other NSAID.~* Allergy or hypersensitivity to triptans.~* Participated in an investigational drug trial in the previous 4 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Treximet (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).